KALA BIO, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $18.3M
- Price
- $0.9102
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.58%
- Volume
- 118.0K
About
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Quick stats
Shares outstanding19.3M
Computed float15.9M
Float / shares82.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001479419
Websitehttps://www.kalarx.com
AI Summary
AI-generated1/4
standardbearishrestructuring
KALA BIO Announces Reverse Stock Split
KALA BIO announced a 1-for-50 reverse stock split effective after the market closes on May 8, 2026, reducing outstanding shares from approximately 929.5 million to 18.6 million.
Trading on a split-adjusted basis will begin on May 11, 2026, under the existing ticker KALA with a new CUSIP number, while the company remains listed on the Nasdaq Capital Market.
Shareholders originally authorized the board to execute a split between 1-for-2 and 1-for-100 at a special meeting in January, with the specific ratio chosen to support the company's listing compliance.
Red flags
- 1-for-50 reverse split indicates significant share price distress
- risk factors highlight uncertainty regarding maintaining Nasdaq listing